接受大剂量胰岛素治疗的心脏毒性暴露患者的死亡危险因素:国家中毒数据系统分析
该研究利用美国国家中毒数据系统2019至2021年数据,纳入1856例接受大剂量胰岛素/葡萄糖治疗的惠者,主要暴露为钙通道阻滞剂(1116例,60%)和β受体阻滞剂(985例,53%)。死亡431例(23%),钙通道阻滞剂暴露较β受体阻滞剂暴露与死亡显著相关(OR 2.2;95%CI 1.6-3.8),维拉帕米较氨氯地平或地尔硫䓬与死亡相关(OR 1.7;95%CI 1.0-2.7)。年龄增加、高血糖、心脏传导阻滞、机械通气或血管加压药治疗均与死亡相关。氨氯地平暴露患者更常用亚甲蓝(16% vs 2%,P<0.001),提示更顽固的血管麻痹。
要点
- 钙通道阻滞剂暴露较β受体阻滞剂暴露与死亡显著相关(OR 2.2;95%CI 1.6-3.8)。
- 维拉帕米较氨氯地平或地尔硫䓬与死亡相关(OR 1.7;95%CI 1.0-2.7)。
- 死亡431例(23%),致命性暴露中最常见心脏毒性药物为氨氯地平(202例,47%)。
- 年龄增加、高血糖、心脏传导阻滞、机械通气或血管加压药治疗均与死亡相关。
- 氨氯地平暴露患者亚甲蓝使用率16%(110/677)高于维拉帕米或地尔硫䓬2%(7/325),P<0.001。
适用人群与场景
- 2019至2021年美国国家中毒数据系统®中建议或实施「大剂量胰岛素/葡萄糖」治疗的病例。
- 主要暴露为钙通道阻滞剂(n=1116,60%)和β受体阻滞剂(n=985,53%)。
研究设计与关键结果
- 研究类型为基于国家中毒数据系统®的数据库分析,纳入1856例接受大剂量胰岛素治疗的患者。
- 死亡431例(23%);致命性暴露中最常见心脏毒性药物为氨氯地平(n=202,47%)。
- 钙通道阻滞剂暴露较β受体阻滞剂暴露与死亡显著相关(OR 2.2;95%CI 1.6-3.8)。
- 维拉帕米较氨氯地平或地尔硫䓬与死亡相关(OR 1.7;95%CI 1.0-2.7)。
- 年龄增加、高血糖、心脏传导阻滞、机械通气或血管加压药治疗均与死亡相关。
- 亚甲蓝在氨氯地平暴露患者中使用率16%(110/677),高于维拉帕米或地尔硫䓬暴露患者的2%(7/325),P<0.001。
证据类型、等级与局限
- 证据类型为基于国家中毒数据系统®的数据库分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,由于大剂量胰岛素是血管扩张剂,需要更多数据以更好界定大剂量胰岛素在氨氯地平中毒中的作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: High-dose insulin/glucose is an inotrope, vasodilator, and standard therapy for beta-adrenoceptor and calcium channel blocker poisoning, yet no large database studies have examined its use. This study sought to describe high-dose insulin use in the United States using the National Poison Data System®. Determining mortality risk factors was the primary aim.
METHODS: We identified all National Poison Data System® cases in which "High dose insulin/glucose" therapy was Recommended or Performed from 2019 to 2021, the first three years National Poison Data System® allowed specific coding for high-dose insulin. We developed logistic regression models to determine clinical factors associated with death in patients receiving high-dose insulin. We also evaluated methylthioninium chloride (methylene blue) use as a refractory vasoplegia marker.
RESULTS: High-dose insulin was used in 1,856 patients, primarily for exposures to calcium channel blockers (n = 1,116 [60%]) and beta-adrenoceptor blockers (n = 985 [53%]), with the most common drugs being amlodipine (n = 677 [61%]) and metoprolol (n = 371 [38%]). Death occurred in 431 [23%] patients; amlodipine was the most common cardiotoxicant in fatal exposures (n = 202 [47%]). Calcium channel blocker exposure was significantly associated with death compared to beta-adrenoceptor blockers (odds ratio 2.2; 95% CI: 1.6-3.8). Exposure to verapamil, compared to amlodipine or diltiazem, was associated with death (odds ratio 1.7; 95% CI: 1.0-2.7). Increasing age, hyperglycemia, heart block, and concomitant treatment with mechanical ventilation or vasopressors were all associated with death. Methylthioninium chloride was more commonly used in patients with amlodipine exposures (110/677 [16%]) than with verapamil or diltiazem (7/325 [2%]; P <0.001).
DISCUSSION: Among patients treated with high-dose insulin, amlodipine-exposed patients were more commonly treated with methylthioninium chloride, suggesting they experienced more refractory vasoplegia. As high-dose insulin is a vasodilator, more data are needed to better define the role for high-dose insulin in amlodipine poisoning.
CONCLUSION: In this study of patients treated with high-dose insulin, exposure to calcium channel blockers was more lethal than beta-adrenoceptor blocker poisoning. Amlodipine was the most common cardiotoxicant in patients who lived or died, while verapamil was the most lethal cardiotoxicant.
参考来源
- Cole JB, Ulici A, Lee SC, et al. Mortality risk factors for patients with cardiotoxic exposures treated with high-dose insulin: analysis of the National Poison Data System®. Clin Toxicol (Phila). 2025. PMID: 40462745. doi:10.1080/15563650.2025.2502613
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。